Vol 4, No 3 (2019)
Research paper
Published online: 2019-08-11

open access

Page views 670
Article views/downloads 617
Get Citation

Connect on Social Media

Connect on Social Media

Galectin-3: a novel blood test for the classification of patients with COPD. An observational study

Togay Evrin1, Bulut Demirel2, Lukasz Szarpak3, Damian Gorczyca3, Nalan Ogan4, Tuba Çandarlı5, Zamir Kemal Ertürk6, Atila Korkmaz1, Matt Hutcherson7, Kurt Ruetzler8, Gülhan Meral4
Disaster Emerg Med J 2019;4(3):77-82.

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is one of the major causes of mortality and mortality affecting the whole world. In the inflammatory process, lectin is elevated and consequently, Galectin-3 expression is increased. This relation has been revealed by studies on coronary diseases. However, studies on the association of Galectin-3 with COPD and even other pulmonary diseases have been limited, although it has been studied and described on cardiologic patients. For this reason, in this study Galectin-3 levels in different stages of COPD patients were investigated and whether Galectin-3 could be a guide clinically. 

MATERIAL AND METHODS: This is an observational prospective study, approved by local ethic committee (30112015-12), which included three groups of patients, COPD exacerbation, COPD stable and control group, admitted to tertiary healthcare between 01.09.2016 and 01.09.2017. 

RESULTS: 137 subjects were included in the study. The mean age of patients in the study was 70.6. Galectin- 3 level in the group of COPD (exacerbation and stable) was significantly lower than the control group (p < 0.001). The Galectin-3 level was significantly lower in COPD exacerbation group than groups of stable COPD and control. And also, Galectin-3 level was significantly lower in stable COPD group than the control group (p values: 0.034, 0.001 and 0.013, respectively). The ROC analysis for the Galectin-3 levels between the COPD patients (exacerbation and stable) and the control group is shown in Figure 2 (AUC = 0.784). When the cut-off points of Galectin-3 is selected as 11.4; for this cut-off point, sensitivity is 83% and specificity is 71% for this cut-off point (AUC: 0.79 %95 GA: 0.70–0.86 p < 0.001). 

CONCLUSIONS: COPD is a disease with high mortality and morbidity and efforts are being made to identify its severity and exacerbations with various biomarkers. In this study, Galectin-3 levels were found to be lower in patients with stable COPD group according to the control group. In addition, galactin-3 levels were found to be lower in COPD exacerbation group according to both Stable COPD group and control group. Although a certain threshold value was found in this study, more studies are needed to determine this threshold value more precisely. However, it is clear that these data are promising.

Article available in PDF format

View PDF Download PDF file

References

  1. Yawn BBp, Thomashaw B, Mannino DM, et al. The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide. Chronic Obstr Pulm Dis. 2017; 4(3): 177–185.
  2. Gold PM. The 2007 GOLD Guidelines: a comprehensive care framework. Respir Care. 2009; 54(8): 1040–1049.
  3. Tan WC, Bourbeau J, Aaron SD, et al. Global Initiative for Chronic Obstructive Lung Disease 2017 Classification and Lung Function Decline in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018; 197(5): 670–673.
  4. Bourdin A, Burgel PR, Chanez P, et al. Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. Eur Respir Rev. 2009; 18(114): 198–212.
  5. Fabbri L, Romagnoli M, Corbetta L, et al. Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2003; 167(3): 418–424.
  6. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996; 93(13): 6737–6742.
  7. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760(4): 616–635.
  8. Hsu DK, Yang RY, Pan Z, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol. 2000; 156(3): 1073–1083.
  9. Jarad N. Chronic obstructive pulmonary disease (COPD) and old age? Chron Respir Dis. 2011; 8(2): 143–151.
  10. Çolak Y, Afzal S, Nordestgaard BG, et al. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med. 2017; 5(5): 426–434.
  11. Mannino DM. Does Undiagnosed Chronic Obstructive Pulmonary Disease Matter? Am J Respir Crit Care Med. 2016; 194(3): 250–252.
  12. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006; 28(6): 1245–1257.
  13. Mukaro VR, Bylund J, Hodge G, et al. Lectins offer new perspectives in the development of macrophage-targeted therapies for COPD/emphysema. PLoS One. 2013; 8(2): e56147.
  14. Dobashi K, Aihara M, Araki T, et al. Regulation of LPS induced IL-12 production by IFN-gamma and IL-4 through intracellular glutathione status in human alveolar macrophages. Clin Exp Immunol. 2001; 124(2): 290–296.
  15. Rabinovich GA, Rubinstein N, Toscano MA. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta. 2002; 1572(2-3): 274–284.
  16. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998; 58(14): 3015–3020.
  17. Kleshchenko YY, Moody TN, Furtak VA, et al. Human galectin-3 promotes Trypanosoma cruzi adhesion to human coronary artery smooth muscle cells. Infect Immun. 2004; 72(11): 6717–6721.
  18. van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006; 48(6): 1217–1224.
  19. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010; 12(8): 826–832.



Disaster and Emergency Medicine Journal